Sunday 18 October 2026
Export SEER’s income statement to Excel — free account
Seer, Inc.
SEER Healthcare Biotechnology
Seer, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $16.6 million, up 17.0% from fiscal 2024. In the quarter to June 2026, revenue fell 23.4%, EPS grew 6.06% and free cash flow grew 36.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
2.03
0.01
−0.49%
Follow SEER
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 3 | 4 | 4 | 3 | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Altman Z-Score |
(0.55) | 0.63 | 1.04 | 5.09 | 23.13 | 42.30 | — | — | — |
P/S ratio |
6.34 | 10.16 | 7.43 | 23.57 | 209.81 | 2,044.75 | 1,536.28 | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Altman Z″-Score (non-manufacturers) |
4.62 | 7.75 | 11.48 | 14.34 | 17.77 | 47.70 | 20.40 | — | — |
P/Operating CF |
(9.73) | (12.57) | (12.16) | (25.62) | (112.24) | (244.55) | (105.78) | — | — |
Beneish M-Score |
(2.98) | (3.28) | (2.18) | (1.92) | 56.54 | 0.62 | — | — | — |
P/B ratio |
0.41 | 0.44 | 0.31 | 0.82 | 2.76 | 3.11 | 0.00 | — | — |
Price to Tangible BV |
0.41 | 0.44 | 0.31 | 0.82 | 2.76 | 3.11 | 0.00 | — | — |
EV/Sales |
(4.87) | (6.52) | (11.55) | (3.61) | 149.35 | 1,386.42 | 1,308.71 | — | — |
EV/EBITDA |
1.14 | 1.02 | 1.76 | 0.60 | 0.00 | 0.00 | 0.00 | — | — |
EV/Operating CF |
1.82 | 2.00 | 3.26 | 0.92 | (21.32) | (43.67) | (17.41) | — | — |
EV/FCF |
1.77 | 1.87 | 2.90 | 0.79 | (18.55) | (35.86) | (13.39) | — | — |
Quick Ratio |
12.23 | 15.83 | 24.42 | 34.03 | 30.11 | 53.39 | 22.63 | 8.40 | — |
Current Ratio |
12.84 | 16.53 | 25.00 | 34.57 | 30.67 | 53.51 | 22.75 | 8.46 | — |
Net Debt/EBITDA |
2.63 | 2.60 | 2.89 | 4.48 | 5.91 | 13.59 | 5.23 | 4.65 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.05 | 0.04 | 0.04 | 0.03 | 0.01 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.60 | 0.53 | 0.68 | 0.65 | 0.65 | 0.64 | 0.82 | 0.74 | — |
Capex/Depreciation |
(0.16) | (0.35) | 1.22 | (3.25) | (1.84) | (2.43) | (9.35) | 0.00 | — |
Interest Coverage |
— | — | — | (21.13) | (3,248.77) | (38.11) | (3,376.60) | (29.97) | — |
| (25.08%) | (23.91%) | (20.45%) | (19.57%) | (15.23%) | (15.94%) | 122.84% | 48.31% | — | |
| (22.21%) | (21.57%) | (18.67%) | (18.10%) | (14.50%) | (12.24%) | (25.27%) | (37.43%) | — | |
ROIC |
(66.40%) | (68.63%) | (80.15%) | (235.97%) | (43.44%) | 0.00% | (636.04%) | 0.00% | — |
Return on Tangible Assets |
(36.69%) | (33.75%) | (25.41%) | (21.04%) | (17.30%) | (7.56%) | (18.09%) | (21.11%) | — |
Average Days of Receivables |
131.05 | 160.45 | 147.13 | 165.34 | 228.59 | 145.78 | 1,025.78 | 0.00 | — |
Research and Development Expense of Revenue |
264.65% | 356.99% | 318.22% | 295.60% | 440.09% | 2,887.50% | 10,683.62% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
256.86% | 399.23% | 353.82% | 377.79% | 691.61% | 2,341.92% | 3,970.69% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
92.98% | 199.06% | 206.61% | 217.34% | 391.82% | 1,120.12% | 1,342.24% | — | — |
Graham Net Nets |
1.57 | 1.49 | 2.35 | 1.08 | 0.27 | 0.31 | 0.15 | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Earnings Yield |
(69.95%) | (60.17%) | (70.10%) | (25.47%) | (5.09%) | (4.60%) | (3.76%) | — | — |
Free Cash Flow Yield |
(43.37%) | (34.27%) | (53.58%) | (19.41%) | (3.84%) | (1.89%) | (6.36%) | — | — |
Revenue per Share |
0.29 | 0.23 | 0.26 | 0.25 | 0.11 | 0.05 | 0.02 | 0.00 | — |
Operating CF per Share |
(0.77) | (0.74) | (0.93) | (0.97) | (0.76) | (1.58) | (1.88) | (0.08) | — |
Capex per Share |
(0.02) | (0.05) | (0.11) | (0.16) | (0.11) | (0.34) | (0.59) | 0.00 | — |
Free Cash Flow per Share |
(0.79) | (0.79) | (1.04) | (1.14) | (0.88) | (1.92) | (2.47) | (0.08) | — |
Cash per Share |
3.24 | 3.79 | 4.95 | 6.75 | 6.57 | 32.68 | 12.37 | 0.51 | — |
Shareholders Equity per Share |
4.51 | 5.25 | 6.22 | 7.16 | 8.26 | 32.66 | 12.61 | 0.49 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
4.51 | 5.25 | 6.22 | 7.16 | 8.26 | 32.66 | 12.61 | 0.49 | — |
Free Cash Flow |
(45.60) | (49.35) | (66.37) | (70.87) | (53.27) | (25.36) | (17.20) | (4.65) | — |
Working Capital |
185.84 | 238.00 | 317.29 | 422.40 | 398.28 | 425.03 | 82.99 | 27.52 | — |
Capital Expenditures |
(1.15) | (3.24) | (7.31) | (10.09) | (6.92) | (4.53) | (4.13) | (0.17) | — |
Net Current Asset Value |
164.76 | 214.30 | 291.15 | 394.05 | 375.48 | 422.42 | 81.25 | 27.49 | — |
EV/EBIT |
1.04 | 0.92 | 1.86 | 0.58 | 0.00 | 0.00 | 0.00 | — | — |
Capex to Sales |
0.07 | 0.23 | 0.44 | 0.65 | 1.05 | 6.91 | 35.61 | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.49 | 0.50 | (0.27) | 0.16 | 0.29 | 0.22 | 0.08 | 0.01 | — |
Cash ROIC |
(10.24%) | (8.75%) | (9.31%) | (8.16%) | (5.90%) | (2.94%) | (9.90%) | (7.63%) | — |
Accounts Receivable Turnover |
2.72 | 2.19 | 2.43 | 2.78 | 3.00 | 2.23 | 0.59 | 0.00 | — |
Accounts Payable Turnover |
1.59 | 2.38 | 4.69 | 2.85 | 1.09 | 0.00 | 0.42 | 0.06 | — |
Inventory Turnover |
1.07 | 1.19 | 1.79 | 1.92 | 1.37 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
252.44 | 237.06 | 61.32 | 91.42 | 431.51 | 0.00 | 365.00 | 9,581.25 | — |
Days of Inventory on Hand |
350.69 | 381.47 | 201.01 | 201.05 | 472.05 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
6.09 | 6.47 | 6.87 | 5.58 | 2.20 | 0.29 | 0.20 | 0.20 | — |
Average Payables |
5.12 | 3.00 | 1.74 | 2.95 | 2.95 | 1.41 | 1.66 | 1.66 | — |
Average Inventory |
7.62 | 5.96 | 4.56 | 4.39 | 2.35 | 2.35 | — | — | — |
Average Assets |
331.34 | 401.43 | 462.10 | 513.53 | 490.73 | 267.78 | 63.47 | 16.85 | — |
Average Common Equity |
293.44 | 362.24 | 421.95 | 474.95 | 467.26 | 205.67 | (13.06) | (13.06) | — |
Columns are period end dates